Lilly: Still Cautious on 2003 Expectations

Semtech sinks; UnitedHealth affirms earnings outlook; plus more of today's stocks in the news

Eli Lilly (LLY ) says the FDA approved Forteo treatment for osteoporosis. The drug giant reiterated its $2.55-$2.57 2002 earnings per share guidance, and is still cautious about 2003 financial assumptions. Earlier Tuesday Friedman downgraded on valuation and the potential for drug launch delays and manufacturing issues, almong other risks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.